Clinical Trials
3 trialsNCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT00710892 2025-07-11
CASPALLO
Baylor College of Medicine
Phase 1 Active not recruiting